Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial

Table 7 Within- and between-group changes in quality of life over 12 weeks

	Baseline		Week 12		Within-group mean change over 12 weeks^a	Between-group mean change over 12 weeks^b
Outcome	n	Mean ± SD	n	Mean ± SD	Mean (95% CI)	Mean (95% CI)	P
Prostate cancer symptoms (FACT-P)
EXE	12	95.1 ± 19.1	12	106.3 ± 24.9	11.7 (0.7, 22.8)	18.0 (1.2, 34.9)	0.04
NoEXE	14	106.1 ± 30.4	14	107.7 ± 30.8	−3.0 (−12.3, 6.2)
General (FACT-G)
EXE	12	69.4 ± 14.1	12	78.4 ± 15.4	8.7 (1.3, 16.2)	11.2 (0.1, 22.2)	0.048
NoEXE	14	83.2 ± 15.5	14	80.6 ± 17.5	−2.5 (−9.2, 4.3)
Fatigue (BFI)
EXE	12	4.2 ± 2.4	12	2.5 ± 2.0	−1.1 (−2.3, 0.1)	− 0.8 (− 2.6, 1.0)	0.36
NoEXE	14	3.2 ± 2.9	14	2.6 ± 2.8	−0.2 (−1.4, 0.9)
Depression (CES-D)
EXE	12	15.3 ± 9.8	12	11.5 ± 6.5	−2.5 (−6.7, 1.8)	−2.8 (−8.9, 3.3)	0.34
NoEXE	14	12.6 ± 11.2	14	9.3 ± 8.6	−1.5 (−5.5, 2.5)

Data presented as mean ± standard deviation. P, significance level; EXE, exercise groups (TRAINPRO and TRAIN); NoEXE, non-exercise groups (PRO and STRETCH)
^aEXE relative to NoEXE adjusted for baseline values
^bEXE relative to NoEXE adjusted for baseline values, protein supplementation, body mass index and number of comorbidities

ISSN: 1471-2407